Caris Life Sciences Publishes Q3 2026 Financial Results Presentation
Bitget2026/11/04 21:26- Caris Life Sciences reported third-quarter 2026 revenue of $275.4 million, up 27% year over year.
- Clinical case volume rose 21% to approximately 61,500; molecular profiling revenue increased 27% to $262.7 million.
- Adjusted EBITDA reached $44.4 million, marking a sixth consecutive positive quarter; GAAP net income totaled $15.3 million.
- Nine-month revenue totaled $755.2 million; cash and securities stood at $769.2 million.
- Caris Assure therapy response monitoring launched, with Caris Confirm minimal residual disease testing scheduled for December 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
